Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: New England Journal of Medicine
Authors: Yi-Long Wu, Maximilian Hochmair, Yi Yang, Xue-Ning Yang, Masahiro Tsuboi, Luis Paz-Ares, James Chih-Hsin Yang, Lin Wu, Hye Ryun Kim, Damian T. Rieke, Melissa Johnson, Benjamin Besse, Nivedita Sharma, Patricia Maeda, Patrick Peterson, Boris Kin Lin, Bente Frimodt-Moller, Jonathan Goldman, Alexander Drilon
Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Third People's Hospital of Chengdu, Southwest Jiaotong University, National Cancer Center Hospital East, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, National Taiwan University Hospital, Hunan Cancer Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Eli Lilly (United States), University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W7162956606